Abstract
Background COVID-19 is associated with long-term pulmonary symptoms and may result in chronic pulmonary impairment. The optimal procedures to prevent, identify, monitor, and treat these pulmonary sequelae are elusive.
Research question To characterize the kinetics of pulmonary recovery, risk factors and constellations of clinical features linked to persisting radiological lung findings after COVID-19.
Study design and methods A longitudinal, prospective, multicenter, observational cohort study including COVID-19 patients (n = 108). Longitudinal pulmonary imaging and functional readouts, symptom prevalence, clinical and laboratory parameters were collected during acute COVID-19 and at 60-, 100- and 180-days follow-up visits. Recovery kinetics and risk factors were investigated by logistic regression. Classification of clinical features and study participants was accomplished by k-means clustering, the k-nearest neighbors (kNN), and naive Bayes algorithms.
Results At the six-month follow-up, 51.9% of participants reported persistent symptoms with physical performance impairment (27.8%) and dyspnea (24.1%) being the most frequent. Structural lung abnormalities were still present in 45.4% of the collective, ranging from 12% in the outpatients to 78% in the subjects treated at the ICU during acute infection. The strongest risk factors of persisting lung findings were elevated interleukin-6 (IL6) and C-reactive protein (CRP) during recovery and hospitalization during acute COVID-19. Clustering analysis revealed association of the lung lesions with increased anti-S1/S2 antibody, IL6, CRP, and D-dimer levels at the early follow-up suggesting non-resolving inflammation as a mechanism of the perturbed recovery.
Finally, we demonstrate the robustness of risk class assignment and prediction of individual risk of delayed lung recovery employing clustering and machine learning algorithms.
Interpretation Severity of acute infection, and systemic inflammation is strongly linked to persistent post-COVID-19 lung abnormality. Automated screening of multi-parameter health record data may assist the identification of patients at risk of delayed pulmonary recovery and optimize COVID-19 follow-up management.
Clinical Trial Registration ClinicalTrials.gov: NCT04416100
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04416100
Clinical Protocols
https://erj.ersjournals.com/content/57/4/2003481.figures-only#fig-data-supplementary-materials
Funding Statement
The study was funded by the research fund of the state of Tyrol (Project GZ 71934, J.LR.) and an Investigator-Initiated Study grant by Boehringer Ingelheim (IIS 1199-0424, I.T.). The funding bodies had no influence on the development of the research and manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board at the Medical University of Innsbruck (approval number: 1103/2020)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of interest The authors declare no conflict of interest related to this study.
Funding information The study was funded by the research fund of the state of Tyrol (Project GZ 71934, J.LR.) and an Investigator-Initiated Study grant by Boehringer Ingelheim (IIS 1199-0424, I.T.). The funding bodies had no influence on the development of the research and manuscript.
Data Availability
As the longitudinal data presented in the manuscript refer to an ongoing study, the complete data set will be made available as soon as the study is completed.
Abbreviations
- ARDS
- acute respiratory distress syndrome
- SARS
- severe acute respiratory syndrome
- CI
- confidence interval
- COVID-19
- coronavirus disease
- 2019 CRP
- C-reactive protein
- CT
- computed tomography
- CVD
- cardiovascular disease
- GGO
- ground-glass opacity
- IL6
- interleukin-6
- kNN
- k nearest neighbors
- LRT
- likelihood ratio test
- NT-proBNP
- N-terminal pro brain natriuretic peptide
- OR
- odds ratio
- SARS-CoV2
- severe acute respiratory syndrome coronavirus 2
